![Siemens Healthineers](https://marketing.webassets.siemens-healthineers.com/b741b8d912c35ef2/cb4bdade86f7/v/742a0a32950e/CC_woman_Oriane01_Overlay_Scientific_014_erw.png)
Ultrasound Derived Fat Fraction (UDFF) White Paper Delivering early liver diagnosis: the difference is in the details
![ACUSON Sequoia Reflection](https://marketing.webassets.siemens-healthineers.com/070834f6dcd1138c/2304cb8d9915/v/f8230367a077/SHS_US_44841_18_reflection02.png)
MASLD (Metabolic dysfunction-associated steatotic liver disease) is the most common cause of chronic liver disease globally. 20% to 30% of people with a MASLD diagnosis progress to a MASH diagnosis (Metabolic dysfunction-associated steatohepatitis), which can lead to advanced fibrosis, cirrhosis, or liver failure with an estimated lifetime cost of $222B in inpatient care.
Qualitative assessment of hepatic steatosis can be subjective. Conventional methods of ultrasound-based liver fat quantification can be difficult to understand. Ultrasound Derived Fat Fraction (UDFF) on the ACUSON Sequoia is fast, simple and intuitive. UDFF, with a total exam time of less than 1 minute, can classify hepatic steatosis as an index value greater than 5%*, delivering a similar clinical utility as MRI-PDFF1,2.
Download the UDFF white paper to learn how to manage hepatic steatosis through liver fat quantification, to aid in successful clinical assessment.